Clarity expands manufacturing capabilities for its Cu-64 SAR-bisPSMA clinical programs
Sydney, Australia 11 August 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, has signed a supply agreement with 3D Imaging LLC. (3DI), a Contract Development and Manufacturing Organisation (CDMO), covering Clarity’s diagnostic 64Cu SAR-bisPSMA product. The new agreement, effective on August 11th, 2022,…